24Jul/13

Pneumonie à Pneumocystis : une complication des traitements par rituximab – Journal International de Médecine (Inscription)

Pneumonie à Pneumocystis : une complication des traitements par rituximab
Journal International de Médecine (Inscription)
La pneumonie à Pneumocystis (PP) reste une infection fongique grave affectant les malades immunodéprimés. Les défenses immunitaires principales contre ce germe opportuniste sont constitués classiquement par les lymphocytes T CD4 +. Mais des études 

24Jul/13

Harbour Antibodies BV Raises €2.5M ($3.3M) to Accelerate the Development of … – PipelineReview.com (press release)

Harbour Antibodies BV Raises €2.5M ($3.3M) to Accelerate the Development of
PipelineReview.com (press release)
ROTTERDAM, The Netherlands & CAMBRIDGE, MA, USA I July 24, 2013 I Harbour Antibodies BV, the creator of transgenic mice to aid in the discovery of new human antibody-based therapies, has raised €2.5M ($3.3M) to continue R&D and commercialize 

24Jul/13

Two decades after Canada's tainted-blood inquiry, new blood donation rules … – Vancouver Sun


Vancouver Sun

Two decades after Canada’s tainted-blood inquiry, new blood donation rules
Vancouver Sun
MONTREAL – A new blood-donation policy came into effect across Canada on Monday, officially nixing the lifelong ban that prevented men who have had sex with men from giving blood. Canadian Blood Services and HEMA-Quebec — which oversee 
20 years after tainted-blood inquiry, new blood donation rules take effectYahoo! News Canada
Health benefits of donating bloodJamaica Gleaner

all 9 news articles »

24Jul/13

Harbour Antibodies BV Raises €2.5M ($3.3M) to Accelerate the Development of … – Fort Mills Times

Harbour Antibodies BV Raises €2.5M ($3.3M) to Accelerate the Development of
Fort Mills Times
Harbour Antibodies BV, the creator of transgenic mice to aid in the discovery of new human antibody-based therapies, has raised €2.5M ($3.3M) to continue R&D and commercialize its technologies. The round was led by Atlas Venture. With the funding 
Harbour Antibodies Licenses H2L2 Mice to PfizerPharmiWeb.com (press release)
Atlas leads €2.5m round for Harbour Antibodiesunquote news (subscription)
Pfizer licenses antibody tech from Atlas-backed startup HarbourFierceBiotech

all 4 news articles »